Personalis, AstraZeneca Extend Collaboration Around Residual Cancer Detection Test
Personalis will use its NeXT Personal molecular residual disease assay to track emerging recurrence in at least one AstraZeneca drug trial.
Caris Life Sciences, ConcertAI Partner on Molecular Oncology R&D Platform
Caris and ConcertAI will combine their multiomic and multimodal databases and AI technology to create a unified platform for use in oncology and hematology.
Envisagenics, Cancer Research UK, Queen Mary University Collaborate on AML Drug R&D
Cold Spring Harbor spinout Envisagenics will apply its AI technology to multiomics data in pursuit of new therapies for acute myeloid leukemia and other hematopoietic cancers.
Envisagenics, Bristol Myers Squibb Partner to ID Cancer Therapy Alternative Splice Targets
Envisagenics will use its SpliceCore platform to identify alternative splicing-derived therapeutic targets for BMS's cancer pipeline.
Genomenon Partners With Neurodevelopmental Disease Groups on Drug Development
The Ann Arbor, Michigan-based bioinformatics company will provide AI-driven genomic data analysis in search of precision treatments for several rare pediatric disorders.